ANIP · NASDAQ
Healthcare · Drug Manufacturers - Specialty & Generic
$73.16
+2.02%
Close on Oct 29, 2026
Research data through 2026-10-28
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Free research · no account required
Research data through Oct 28, 2026. Research is updated periodically, not in real time.
79
of 100 · stored research reading
Stored Quality research reads 79 of 100, an above-average reading in the covered universe. Some underlying measurements are stronger than others.
Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.
How this is measured58
of 100 · stored research reading
Stored Fundamental Momentum research reads 58 of 100. Stored measurements classify recent reported fundamentals as middle. This describes reported financial change already disclosed, with no forward-looking claim.
Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.
How this is measured29
of 100 · stored research reading
Stored Capital Returns research reads 29 of 100, recorded as weak. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has increased at about 12.6% a year in the stored window.
Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.
How this is measuredStored ratios recorded at the last research date (2026-10-28). Valuation Intelligence remains research context and is not a validated allocation signal.
Learn the basics of valuationInvestor intelligence
The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.
Investor
Unlock its Pro Investor Score and ranking across the research universe.
7 days · No credit card required
Investor
Unlock Risk Intelligence, Price Risk, and Market Confirmation.
7 days · No credit card required
Investor
Unlock the Pro Research Brief with What Changed & Why, research history and tensions.
7 days · No credit card required
Investor
Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.
7 days · No credit card required
Investor
Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.
7 days · No credit card required
Investor
Save companies and monitor how their research changes over time.
7 days · No credit card required
Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.
Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.
Appears in
Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.
Plain-English definitions, with the formula and the limitations of each measure.
In the company’s own words
ANI Pharmaceuticals is a diversified bio-pharmaceutical company. The Company's mission is "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses.
On September 16, 2024, the Company acquired Alimera Sciences, Inc. ("Alimera"). In connection with the acquisition, the Company added two new products, ILUVIEN ("ILUVIEN") and YUTIQ ("YUTIQ"). See Note 3 "Business Combination" in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.
During March 2025, the FDA approved an expanded label for ILUVIEN to include an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye ("NIU-PS") in addition to the then-current indication of Diabetic Macular Edema ("DME"). The Company is currently marketing ILUVIEN for both indications in the U.S. ILUVIEN was already approved for both DME and NIU-PS outside the U.S., including in seventeen European countries. During the second quarter of 2025, the Company transitioned promotional efforts in the U.S. from YUTIQ to ILUVIEN with its combined label of DME and NIU-PS.
The Company owns and operates three pharmaceutical manufacturing facilities, including two facilities in Baudette, Minnesota and one in East Windsor, New Jersey, which collectively are capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company ceased operations at another manufacturing facility in Oakville, Ontario as of March 31, 2023. See Note 4 "Restructuring Canada Operations" in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.
Quoted from the business section of this company’s 10-K filed February 27, 2026. Read the filing
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.
